In mouse models, inhibition of HIF transcriptional activity has significant effects on tumor vascularization, cancer stem cell specification, metastasis, and immune evasion2,73, suggesting that the potential therapeutic effects of DNA-PK inhibitors in breast cancer may be due in part to their inhibition of HIF transcriptional activity. Here, PRKDC is linked to breast cancer.